Stock Update (NASDAQ:GWPH): The Lancet Neurology Publishes Data From GW Pharmaceuticals PLC- ADR Epidiolex® Expanded Access Program in Children and Young Adults With Treatment-Resistant Epilepsy

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform,  announced that Epidiolex® (cannabidiol or CBD) data from the physician-led expanded access program in treatment-resistant epilepsy were published in The Lancet Neurology1.  

The published paper reports that Epidiolex reduced seizure frequency across multiple drug-resistant epilepsy syndromes and seizure types and was generally well tolerated. The authors note that the administration of Epidiolex as an add-on treatment led to a clinically meaningful reduction in seizure frequency in many patients and had an adequate safety profile in this patient population with highly treatment-resistant epilepsies. The safety and tolerability profile of Epidiolex was favorable with only 3 percent of patients terminating therapy due to an adverse event. The authors note that without a control group, the results regarding efficacy and safety should be interpreted cautiously.

“We are pleased that The Lancet Neurology has chosen to report these promising data on a significant number of patients with very challenging forms of epilepsy,” said lead author Orrin Devinsky, M.D., of New York University Langone Medical Center’s Comprehensive Epilepsy Center. “These data reinforce and support the safety and efficacy we have shared in previous studies. Most importantly the results are providing hope to the children and their families who have been living with debilitating seizures. Further study is needed before results can be confirmed and randomized controlled studies are now underway to help us better understand the effectiveness of the drug. We very much look forward to the results from these studies in 2016.”

The expanded access program is a non-placebo controlled “compassionate access” program carried out by individual investigators independent from GW. Patients enrolled in the expanded access program were some of the most treatment-resistant patients being treated at each of the epilepsy centers. Prior to participating in the expanded access program, many of these patients failed to achieve seizure control despite treatment with antiepileptic drugs, dietary therapies, surgical therapies, and vagus nerve stimulation. The median number of concomitant antiepileptic drugs at the start of the trial was three. Data in the paper are from 11 independent epilepsy centers in the U.S.; 162 patients who had at least 12 weeks of follow-up after the first dose of cannabidiol were included in the safety and tolerability analysis, and 137 patients were included in the efficacy analysis. Of these 162 patients, there were 33 patients with Dravet syndrome and 31 patients with Lennox-Gastaut syndrome (LGS). Dravet syndrome and LGS are two rare, extremely debilitating epilepsy syndromes that begin in infancy or early childhood. Ninety percent or more of people with Dravet Syndrome and LGS are considered treatment resistant.

The Lancet Neurology paper provides a more expansive description of data previously presented at the American Academy of Neurology Annual Meeting in April 2015. Since that time, additional expanded access data, encompassing almost twice the number of patients, were presented as a late-breaking poster at the American Epilepsy Society Annual Meeting earlier this month2.

“We are pleased that these Epidiolex data were selected for publication in The Lancet Neurology. The treatment effect seen in this open label study of Epidiolex in our initial target indications of Dravet syndrome and Lennox-Gastaut syndrome shows consistency with other data disclosures, and also demonstrates the effect of Epidiolex across multiple drug-resistant epilepsy syndromes and seizure types,” stated Justin Gover, GW’s Chief Executive Officer. “GW’s Phase 3 pivotal safety and efficacy studies in Dravet syndrome and Lennox-Gastaut Syndrome are now nearing completion and will provide the placebo-controlled efficacy and safety profile that patients and physicians have been calling for. We look forward to these results in 2016.”

Treatment effect data analysis used in this publication mainly focused on monthly seizure frequency calculated over the entire 12-week treatment period (including a 4-week dose titration period) compared to monthly seizure frequency during a 4-week baseline observation period. This calculation is similar to the approach being utilized in calculating the U.S. Food and Drug Administration’s (FDA) recommended primary efficacy endpoint in GW’s Epidiolex Phase 3 pivotal trials, which compare percent change in the monthly seizure frequency over the entire 14-week treatment period (including a 2-week dose titration period) to monthly seizure frequency during the 4-week baseline observation period.

Highlights from the publication of particular relevance to GW’s pivotal trials program in Dravet syndrome and LGS include:

  • Dravet syndrome: The median reduction in monthly motor (i.e., convulsive) seizures was 49.8% (n=32). 50% of Dravet syndrome patients had a 50% or greater reduction in monthly motor seizures. During the last 4 weeks of therapy, 13% (n=4) were free of motor seizures; these patients were also free of all other seizure types. In Dravet syndrome patients who experienced them at baseline, there was a median 69.2% reduction in monthly tonic seizures (n=6), 46.7% reduction in monthly tonic-clonic seizures (n=29), and 83.3% reduction in non-motor focal seizures (n=10).
  • LGS: A median 68.8% reduction in average monthly atonic seizures was observed (n=14). During the last 4 weeks of therapy, 21% (n=3) were free of atonic seizures and 3% (n=1) were totally seizure free. In LGS patients who experienced motor and tonic seizures at baseline, there were median 36.8% (n=30) and 44% (n=21) reductions, respectively.
  • Adverse events occurred in 79% of all patients treated with cannabidiol (n=162). Adverse events reported in greater than 10% of patients were somnolence (25%), decreased appetite (19%), diarrhea (19%), fatigue (13%) and convulsion (11%). Most adverse events were mild or moderate and transient. Five patients (3%) discontinued treatment due to an adverse event.
  • Serious adverse events were reported in 48 patients (30%), including one death, regarded as unrelated to CBD. Serious adverse events which were deemed possibly related to CBD occurred in 20 patients. (Original Source)

Shares of GW Pharmaceuticals plc closed yesterday at $67.1, up $2.14 or 3.29%. GWPH has a 1-year high of $133.98 and a 1-year low of $64.78. The stock’s 50-day moving average is $80.27 and its 200-day moving average is $100.59.

On the ratings front, GW Pharmaceuticals has been the subject of a number of recent research reports. In a report issued on December 17, Piper Jaffray analyst Joshua Schimmer maintained a Buy rating on GWPH, with a price target of $147, which implies an upside of 119.1% from current levels. Separately, on September 17, Cowen’s Phil Nadeau reiterated a Buy rating on the stock and has a price target of $135.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Joshua Schimmer and Phil Nadeau have a total average return of -1.6% and 12.7% respectively. Schimmer has a success rate of 43.2% and is ranked #3083 out of 3658 analysts, while Nadeau has a success rate of 54.4% and is ranked #288.

GW Pharmaceuticals PLC is engaged in the research, development and commercialisation of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts